PARP1 and cancer: Upregulation of certain oncogenic pathways such as Wnt/β-catenin signaling pathway or DDR related protein may also confer cancer cells insensitive to PARP inhibitors and providing some rationale for combination strategies with PARP inhibitors (Fukumoto et al., 2019; Watson et al., 2019; Liu et al., 2020).